You Position: Home > Paper

Discontinuation of tyrosine kinase inhibitor therapy: can chronic myeloid leukemia be cured?

( views:334, downloads:184 )
Author:
No author available
Journal Title:
Journal of Leukemia & Lymphoma
Issue:
3
DOI:
10.3760/cma.j.issn.1009-9921.2012.03.001
Key Word:
慢性粒细胞白血病;伊马替尼;停药;微小残留病;Leukemia,myelogenous,chronic;Imatinib;Minimal residual disease

Abstract: It is a crucial question whether it is necessary to continue the treatment after the patients with chronic myeloid leukemia (CML) who have achieved a complete molecular response (CMR) on imatinib (IM) treatment. If tyrosine kinase inhibitor (TKI) therapy was required indefinitely to maintain CMR, the problems of financial burden and adverse effects would be increased. Approximately 40 % of patients with a stable CMR for at least 2 years could stop IM treatment and remain in molecular remission for at least 2 years without IM treatment. Therefore, the ultimate aim should be to give the patients long-term disease control without the need for ongoing treatment. Here the studies progresses of discontinuation of TKI therapy in CML reported in the 53th American Society of Hematology (ASH) annual meeting were reviewed.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn